Navigation Links
Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track
Date:11/1/2007

he Biotechnology Industry Organization (BIO), the Technology Council of Maryland and MdBio. He holds a bachelor's degree in economics and government from Dartmouth College, New Hampshire, USA.

Notes to Editors

Shire plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com

The "Safe Harbor" Statement Under The Private Securities Litigation Reform Act of 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research; product development including, but not limited to, the successful development of JUVISTA(R) (Human TGF beta 3) and GA-GCB (velaglucerase alfa); manufacturing and commercialization including, but not limited to, the launch and establishment in the market of VYVANSE(TM)(lisdexamfetamine dimesylate) (Attent
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. Further support for use of statins in Alzheimer’s disease
2. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
3. Doctor Accused Of Misdiagnosing 208 Patients: Further Investigation Ordered
4. NHS announces further Cost cutting Measures
5. NHS Recommends Further Cost Cutting Measures
6. Medha Patkars Condition Deteriorates Further
7. Oxford Radcliffe Hospitals Warns Of Further Job Losses
8. Asia Arming up to further the AIDS fight
9. Further Studies Needed To Completely Understand About Ventricular Fibrillation
10. Further improvements envisaged at Carstairs
11. UCLA Find Yields Further Insight into Causes of Parkinson’s Diseas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ... July 06, 2015 , ... Acara Partners, a leading business ... of its complimentary educational webinar series for the summer of 2015. ... for their clients through targeted marketing, sales, digital communications, branding and business development ...
(Date:7/6/2015)... ... July 06, 2015 , ... Olive Fertility Centre is proud to announce that ... Award on behalf of the department of Family Practice. , “This award is a ... practicing in. The technology is changing so rapidly and we are also developing new ...
(Date:7/6/2015)... ... July 06, 2015 , ... Cancer Hope Network ... caregivers and medical professionals to chat with the CHN patient services team and ... a cancer diagnosis is often the most traumatic experience of a person’s life,” ...
(Date:7/6/2015)... , ... July 06, 2015 , ... MD Now, the ... July 6. The newly constructed urgent care center will serve residents and visitors in ... addition to being MD Now’s 22nd South Florida location, the new facility will be ...
(Date:7/6/2015)... ... ... World renowned Los Angeles facial plastic surgeon , Dr. Paul Nassif, ... solutions. Individuals that want to make multiple changes to their facial appearance are able ... of their needs. , "Anytime I see an opportunity to change the life ...
Breaking Medicine News(10 mins):Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 3Health News:Los Angeles Plastic Surgeon, Dr. Paul Nassif, is Now Offering Comprehensive Facial Plastic Surgery Procedures 2
... significant bone mass in the first year after the transplant, ... bodies from rejecting the new organ. The bone loss greatly ... fractures among this group ranges from 22 percent to 44 ... but which drugs work best in this situation is unclear. ...
... suggest that kids who struggle to breathe during sleep ... out. ,Adenotonsillectomy is a common surgical procedure in ... performed to treat recurring bouts of tonsillitis. During the ... to treat obstructive sleep apnea (OSA), a condition in ...
... 34 years old. Advances in chemotherapy and radiotherapy have ... cancer, but since men who get the disease are ... and its treatment on fertility remains. ,While ... found fertility rates unchanged. These conflicting results suggested the ...
... has shown that a chemotherapy regimen combining vinorelbine (Navelbine) ... in the treatment of hormone-refractory prostate cancer . Specialists ... earlier in their disease. , However researchers ... treatment regimen is planned. From a group of 66 ...
... failure is a chronic but deadly condition caused by the ... weaker and weaker. An estimated 5 million Americans ... five years. It can be caused by high blood pressure, ... In a recent study it was seen that heart failure ...
... Previous studies show conflicting results over whether hormone replacement ... A recent study examines the pros and cons of ... combined HRT therapy for five years. All the women ... had menopausal symptoms, while others did not.Results show women ...
Cached Medicine News:Health News:A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer 2
(Date:7/6/2015)... , July 6, 2015 Hologic, Inc. (NASDAQ: ... to release its financial results for the third quarter ... the market closes.  In conjunction with the release, management ... p.m. Eastern Time. Interested participants may listen ... the United States ) or 719-325-4804 (for international ...
(Date:7/6/2015)... 2015 E-QURE Corp (OTCQB: EQUR), today announced that ... VirtualInvestorConferences.com on July 9, 2015. DATE: Thursday, July ... This will be a live, interactive ... company questions in real-time - both in the presentation ... If attendees are not able to join the event ...
(Date:7/6/2015)... and FARMINGTON, Conn. ... (NYSE MKT: PTN), a biopharmaceutical company developing targeted, ... with significant unmet medical need and commercial potential, ... private placement of Series E warrants to purchase ... F warrants to purchase 2,191,781 shares of its ...
Breaking Medicine Technology:Hologic to Announce Financial Results for the Third Quarter of Fiscal 2015 on Wednesday, July 29, 2015 2E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9 2Palatin Technologies Completes $30 Million Financing 2Palatin Technologies Completes $30 Million Financing 3Palatin Technologies Completes $30 Million Financing 4Palatin Technologies Completes $30 Million Financing 5
... Weiss, Director of Maryland Laser, Skin and Vein,Institute, ... BALTIMORE, Oct. 2 Robert Weiss, M.D., board ... U.S. to offer his,patients DOT Therapy (Dermal Optical ... Dr. Weiss is an,internationally renowned dermatologist, who is ...
... Biotechnologies AB and Dyax,Corp. (NASDAQ: DYAX ) ... a,collaboration to discover and to develop therapeutic ... inflammatory diseases., The collaboration follows the ... Professors Frostegard and de Faire of the ...
Cached Medicine Technology:DOT Therapy: Newest Breakthrough Technology in Laser Skin Resurfacing 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4
... BX620S. Digital stability control, analog display ... counting and percent measure functions, auto ... and time data from built-in clock. ... (selectable from 200g to 600g). Built-in ...
The EK-H Series offer 10 selectable units of measure...
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
The EK-H Series offer 10 selectable units of measure...
Medicine Products: